Last reviewed · How we verify
NCT06046625
Needs and Preferences of Patients With Head-neck Cutaneous SCC
trial testing Regular care with additional administration of a semi-structured interview in Cutaneous Squamous Cell Carcinoma in 15 participants. Participants enrolled and being followed up; not accepting new ones.
1 November 2023
Quick facts
| Lead sponsor | Maastricht University Medical Center |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 1 November 2021 |
| Primary completion | 1 November 2023 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Regular care with additional administration of a semi-structured interview
Conditions studied
- Cutaneous Squamous Cell Carcinoma — all drugs for Cutaneous Squamous Cell Carcinoma →
- Cutaneous Squamous Cell Carcinoma of the Head and Neck — all drugs for Cutaneous Squamous Cell Carcinoma of the Head and Neck →
- Squamous Cell Carcinoma — all drugs for Squamous Cell Carcinoma →
- Squamous Cell Carcinoma of Head and Neck — all drugs for Squamous Cell Carcinoma of Head and Neck →
Sponsor
Maastricht University Medical Center
Who can join
18 and older, any sex, with Cutaneous Squamous Cell Carcinoma or Cutaneous Squamous Cell Carcinoma of the Head and Neck. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The care of patients with high-risk cutaneous squamous cell carcinomas in the head-neck area is complex and requires a multidisciplinary approach. A key component in this care is the need and experience of patients. However, studies on the experiences and needs of patients with high-risk cutaneous squamous cell carcinomas in the head-neck region are lacking.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06046625
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cutaneous Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
- NCT07402616 — Ex Vivo Cutaneous SCC · NA · recruiting
- NCT06875609 — ctDNA in Cutaneous Squamous Cell Carcinoma · recruiting
- NCT06567314 — Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT06659146 — Thermotherapy in Addition to SOC Palliative Radiotherapy · NA · recruiting
Other Maastricht University Medical Center trials
Trials by the same sponsor.
- NCT04603261 — Time to Excretion of Contrast, a Maastricht Prospective Observational Study · withdrawn
- NCT04598516 — Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30 · withdrawn
- NCT04597892 — Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast · withdrawn
- NCT07287358 — Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II · NA · not yet recruiting
- NCT07501780 — Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06046625 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maastricht University Medical Center
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06046625.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing